BNZ 1

Drug Profile

BNZ 1

Alternative Names: BNZ-1; BNZ132-1; BNZ132-1-40

Latest Information Update: 08 Aug 2016

Price : $50

At a glance

  • Originator Bioniz
  • Developer Bioniz; National Institutes of Health (USA)
  • Class Peptides
  • Mechanism of Action Interleukin 15 receptor antagonists; Interleukin 2 receptor antagonists; Interleukin 9 receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I T-cell leukaemia; Tropical spastic paraparesis

Most Recent Events

  • 01 Aug 2016 Phase-I clinical trials in T-cell leukaemia (In volunteers) in USA (Parenteral)
  • 01 Aug 2016 Phase-I clinical trials in Tropical spastic paraparesis (In volunteers) in USA (Parenteral)
  • 17 Jun 2015 Preclinical trials in T-cell leukaemia in USA (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top